litlas
Log inCreate account

Henry Gómez

Active 1991–2025

Also published as
Henry Gomez
107
Papers
24,553
Citations
70
h-index
103
i10-index

Citations

Citations per year for Henry Gómez1981: 1 citations1991: 2 citations1997: 2 citations1998: 1 citations1999: 4 citations2000: 11 citations2001: 10 citations2002: 4 citations2003: 17 citations2004: 13 citations2005: 14 citations2006: 22 citations2007: 30 citations2008: 60 citations2009: 106 citations2010: 127 citations2011: 155 citations2012: 162 citations2013: 190 citations2014: 178 citations2015: 262 citations2016: 238 citations2017: 242 citations2018: 291 citations2019: 1,025 citations2020: 1,034 citations2021: 992 citations2022: 802 citations2023: 535 citations2024: 962 citations2025: 478 citations2026: 19 citations1982–1990: no citations, so these years are not shown1992–1996: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,965 citing papers, 24.9% of this breakdownChina: 1,131 citing papers, 9.5% of this breakdownItaly: 743 citing papers, 6.2% of this breakdownUnited Kingdom: 675 citing papers, 5.7% of this breakdownGermany: 551 citing papers, 4.6% of this breakdownFrance: 495 citing papers, 4.2% of this breakdownSpain: 416 citing papers, 3.5% of this breakdownCanada: 371 citing papers, 3.1% of this breakdownSwitzerland: 333 citing papers, 2.8% of this breakdownBelgium: 332 citing papers, 2.8% of this breakdownAustralia: 324 citing papers, 2.7% of this breakdownNetherlands: 256 citing papers, 2.1% of this breakdown
0%24.9%Other 27.9%

Institutions

Fields

  • Medicine50.8%
  • Biochemistry, Genetics and Molecular Biology40.8%
  • Immunology and Microbiology2.4%
  • Computer Science1.9%
  • Engineering0.8%
  • Health Professions0.6%
  • Other2.7%

Topics

  • Breast Cancer Treatment Studies8.8%
  • HER2/EGFR in Cancer Research6%
  • Advanced Breast Cancer Therapies4.8%
  • Cancer Immunotherapy and Biomarkers4%
  • Cancer Genomics and Diagnostics3.3%
  • Cancer Cells and Metastasis2.5%
  • Other70.6%

Coauthors

All papers

Open in search
  1. Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

    Authors: Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Javier Cortés, Henry Gómez, Xichun Hu, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Yeon Hee Park, Joohyuk Sohn, Masakazu Toi, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Elza C. de Bruin, Lynda Grinsted, Gaia Schiavon, Andrew Foxley, Hope S. Rugo - New England Journal of Medicine 2023 cited by 704

  2. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Peter M. Ravdin, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, Jeffrey L. Berenberg, Jeffrey S. Abrams, George W. Sledge - New England Journal of Medicine 2018 cited by 2,369

  3. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

    Authors: Kyung‐min Lee, Jennifer M. Giltnane, Justin M. Balko, Luis J. Schwarz, Ángel Guerrero‐Zotano, Katherine E. Hutchinson, Mellissa J. Nixon, Mónica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Taekyu Lee, Henry Gómez, Aňa Lluch, José Alejandro Pérez Fidalgo, Melissa M. Wolf, Gabriela Andrejeva, Jeffrey C. Rathmell, Stephen W. Fesik, Carlos L. Arteaga - Cell Metabolism 2017 cited by 646

  4. Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer

    Authors: Rinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, Garrett M. Frampton, Funda Meric‐Bernstam, Ana M. González-Angulo, Jaime Ferrer-Lozano, José Alejandro Pérez Fidalgo, Massimo Cristofanilli, Henry Gómez, Carlos L. Arteaga, Jennifer M. Giltnane, Justin M. Balko, Maureen Cronin, Mirna Jarosz, James Sun, Matthew Hawryluk, Doron Lipson, Geoff Otto, Jeffrey S. Ross, Addie Dvir, Lior Soussan‐Gutman, Ido Wolf, Tamar Rubinek, Lauren Gilmore, Stuart J. Schnitt, Steven E. Come, Lajos Pusztai, Philip Stephens, Myles Brown, Vincent A. Miller - Clinical Cancer Research 2014 cited by 662

  5. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

    Authors: Prudence A. Francis, Olivia Pagani, Gini F. Fleming, Barbara Walley, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Eva Ciruelos, Harold J. Burstein, Hervé Bonnefoi, Meritxell Bellet, Silvana Martino, Charles E. Geyer, Matthew P. Goetz, Vered Stearns, Graziella Pinotti, Fabio Puglisi, Simon Spazzapan, Miguel Ángel Climent, Lorenzo Pavesi, Thomas Ruhstaller, Nancy E. Davidson, Robert L. Coleman, Marc Debled, Stefan Buchholz, James N. Ingle, Eric P. Winer, Rudolf Maibach, Manuela Rabaglio, Barbara Ruepp, Angelo Di Leo, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan - New England Journal of Medicine 2018 cited by 673

  6. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

    Authors: José Baselga, Ian Bradbury, Holger Eidtmann, Serena Di Cosimo, Evandro de Azambuja, Claudia Aura, Henry Gómez, Phuong Dinh, Karine Fauria, Veerle Van Dooren, Gursel Aktan, Aron Goldhirsch, Tsai-Wang Chang, Zsolt Horváth, M.A. Coccia-Portugal, Julien Dômont, Ling-Min Tseng, Georg Kunz, Joohyuk Sohn, Semiglazov Vf, Guillermo Lerzo, Markéta Palácová, Volodymyr Probachai, Lajos Pusztai, Michael Untch, Richard D. Gelber, Martine Piccart - The Lancet 2012 cited by 1,314

  7. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

    Authors: Olivia Pagani, Barbara Walley, Gini F. Fleming, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Harold J. Burstein, Matthew P. Goetz, Eva Ciruelos, Vered Stearns, Hervé Bonnefoi, Silvana Martino, Charles E. Geyer, Claudio Chini, Fabio Puglisi, Simon Spazzapan, Thomas Ruhstaller, Eric P. Winer, Barbara Ruepp, Sherene Loi, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan, Prudence A. Francis - Journal of Clinical Oncology 2022 cited by 154

  8. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Peter M. Ravdin, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, Jeffrey L. Berenberg, Jeffrey S. Abrams, George W. Sledge - New England Journal of Medicine 2019 cited by 555

  9. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Edith A. Perez, John A. Olson, JoAnne Zujewski, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Peter M. Ravdin, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, James N. Atkins, Jeffrey L. Berenberg, George W. Sledge - New England Journal of Medicine 2015 cited by 1,439

  10. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

    Authors: Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, S.E. Combs, David L. Rimm, Jennifer M. Giltnane, Mónica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, S. Mallal, Kai Wang, Vincent A. Miller, Phil Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko - Clinical Cancer Research 2015 cited by 552

  11. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

    Authors: Olivia Pagani, Meredith M. Regan, Barbara Walley, Gini F. Fleming, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Harold J. Burstein, Edith A. Perez, Eva Ciruelos, Vered Stearns, Hervé Bonnefoi, Silvana Martino, Charles E. Geyer, Graziella Pinotti, Fabio Puglisi, Diana Crivellari, Thomas Ruhstaller, Eric P. Winer, Manuela Rabaglio, Rudolf Maibach, Barbara Ruepp, Anita Giobbie‐Hurder, Karen N. Price, Jürg Bernhard, Weixiu Luo, Karin Ribi, Giuseppe Viale, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Prudence A. Francis - New England Journal of Medicine 2014 cited by 747

  12. NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer

    Authors: Brandie C. Taylor, Xiaopeng Sun, Paula I. González-Ericsson, Violeta Sánchez, Melinda E. Sanders, Elizabeth C. Wescott, Susan R. Opalenik, Ann Hanna, Shu-Ting Chou, Luc Van Kaer, Henry Gómez, Claudine Isaacs, Tarah J. Ballinger, Cesar A. Santa‐Maria, Payal D. Shah, Elizabeth Claire Dees, Brian D. Lehmann, Vandana G. Abramson, Jennifer A. Pietenpol, Justin M. Balko - Cancer Discovery 2023 cited by 63

  13. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

    Authors: Brian D. Lehmann, Joshua A. Bauer, Johanna M. Schafer, Christopher S Pendleton, Luojia Tang, Kimberly C. Johnson, Xi Chen, Justin M. Balko, Henry Gómez, Carlos L. Arteaga, Gordon B. Mills, Melinda E. Sanders, Jennifer A. Pietenpol - Breast Cancer Research 2014 cited by 331

  14. Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

    Authors: Stephen Johnston, John Pippen, Xavier Pivot, Mikhail Lichinitser, Saeed Sadeghi, Véronique Dièras, Henry Gómez, Gilles Romieu, Alexey Manikhas, M. John Kennedy, Michael F. Press, J. Maltzman, Allison Florance, Lisa O’Rourke, Cristina Oliva, Steven Stein, Mark D. Pegram - Journal of Clinical Oncology 2009 cited by 1,024

  15. Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

    Authors: Halle C. F. Moore, Joseph M. Unger, Kelly‐Anne Phillips, Frances Boyle, Erika Hitre, David Porter, Prudence A. Francis, Lori J. Goldstein, Henry Gómez, Carlos Vallejos, Ann H. Partridge, Shaker R. Dakhil, Agustin A. García, Julie R. Gralow, Janine Lombard, John Forbes, Silvana Martino, William E. Barlow, Carol J. Fabian, Lori M. Minasian, Frank L. Meyskens, Richard D. Gelber, Gabriel N. Hortobágyi, Kathy S. Albain - New England Journal of Medicine 2015 cited by 542

  16. Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

    Authors: Justin M. Balko, Jennifer M. Giltnane, Kai Wang, Luis J. Schwarz, Christian D. Young, Rebecca S. Cook, Philip Owens, Melinda E. Sanders, María G. Kuba, Violeta Sánchez, Richard Kurupi, Preston D. Moore, Joseph A. Pinto, Franco D. Doimi, Henry Gómez, Dai Horiuchi, Andrei Goga, Brian D. Lehmann, Joshua A. Bauer, Jennifer A. Pietenpol, Jeffrey S. Ross, Gary A. Palmer, Roman Yelensky, Maureen Cronin, Vincent A. Miller, P. J. Stephens, Carlos L. Arteaga - Cancer Discovery 2013 cited by 477

  17. Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer

    Authors: Paula I. González-Ericsson, Julia D. Wulfkhule, Rosa I. Gallagher, Xiaopeng Sun, Margaret L. Axelrod, Quanhu Sheng, Na Luo, Henry Gómez, Violeta Sánchez, Melinda E. Sanders, Lajos Pusztai, Emanuel Petricoin, Kim Blenman, Justin M. Balko, I-SPY2 Trial Team - Clinical Cancer Research 2021 cited by 91

  18. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT

    Authors: Olivia Pagani, Prudence A. Francis, Gini F. Fleming, Barbara Walley, Giuseppe Viale, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Graziella Pinotti, Angelo Di Leo, Alan S. Coates, Aron Goldhirsch, Richard D. Gelber, Meredith M. Regan, for the SOFT and TEXT Investigators and International Breast Cancer Study Group - Journal of Clinical Oncology 2019 cited by 150

  19. Genomic profiling of ER + breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

    Authors: Jennifer M. Giltnane, Katherine E. Hutchinson, Thomas Stricker, Luigi Formisano, Christian D. Young, Mónica V. Estrada, Mellissa J. Nixon, Liping Du, Violeta Sánchez, Paula I. González-Ericsson, María G. Kuba, Melinda E. Sanders, Xinmeng Jasmine Mu, Eliezer M. Van Allen, Nikhil Wagle, Ingrid A. Mayer, Vandana G. Abramson, Henry Gómez, Monica Rizzo, Weiyi Toy, Sarat Chandarlapaty, Erica L. Mayer, Jason Christiansen, Danielle Murphy, Kerry Fitzgerald, Kai Wang, Jeffrey S. Ross, Vincent A. Miller, P. J. Stephens, Roman Yelensky, Levi A. Garraway, Yu Shyr, Ingrid M. Meszoely, Justin M. Balko, Carlos L. Arteaga - Science Translational Medicine 2017 cited by 124

  20. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?

    Authors: Joseph A. Pinto, Carlos Vallejos, Luis E. Raez, Luís Más, Rossana Ruiz, J. Smith Torres‐Roman, Zaida Morante, Jhajaira M. Araujo, Henry Gómez, Alfredo Aguilar, Denisse Bretel, Claudio Flores, Christian Rolfo - ESMO Open 2018 cited by 168

  21. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

    Authors: Omid Hamid, Henrik Schmidt, Aviram Nissan, Laura Ridolfi, Steinar Aamdal, Johan Hansson, Michele Guida, David M. Hyams, Henry Gómez, Lars Bastholt, Scott D. Chasalow, David M. Berman - Journal of Translational Medicine 2011 cited by 531

  22. Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)

    Authors: Joanne L. Blum, Patrick J. Flynn, Greg Yothers, Lina Asmar, Charles E. Geyer, Samuel A. Jacobs, Nicholas J. Robert, Judith O. Hopkins, Joyce O’Shaughnessy, Chau T. Dang, Henry Gómez, Louis Fehrenbacher, Svetislava J. Vukelja, Alan P. Lyss, Devchand Paul, Adam Brufsky, Jong‐Hyeon Jeong, Linda H. Colangelo, Sandra M. Swain, Eleftherios P. Mamounas, Stephen E. Jones, Norman Wolmark - Journal of Clinical Oncology 2017 cited by 288

  23. Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer

    Authors: Justin M. Balko, Luis J. Schwarz, Neil E. Bhola, Richard Kurupi, Philip Owens, Todd W. Miller, Henry Gómez, Rebecca S. Cook, Carlos L. Arteaga - Cancer Research 2013 cited by 163

  24. Planning cancer control in Latin America and the Caribbean

    Authors: Paul E. Goss, Brittany Lee, Tanja Badovinac-Črnjević, Kathrin Strasser‐Weippl, Yanin Chávarri-Guerra, Jessica St. Louis, Cynthia Villarreal‐Garza, Karla Unger‐Saldaña, Mayra Ferreyra, Márcio Debiasi, Pedro ER Liedke, Diego Touya, Gustavo Werutsky, Michaela J. Higgins, Lei Fan, Cláudia Cristina Ferreira Vasconcelos, Eduardo Cazap, Carlos Vallejos, Alejandro Mohar, Felícia Marie Knaul, Héctor Arreola, Rekha Batura, Silvana Luciani, Richard Sullivan, Dianne M. Finkelstein, Sérgio D. Simon, Carlos H. Barrios, Rebecca S Kightlinger, Andrés Gelrud, Brittany Bychkovsky, Gilberto Lopes, Stephen Stefani, Marcelo Blaya, Fabiano Hahn Souza, Franklin Santana Santos, Alberto Kaemmerer, Evandro de Azambuja, Andres Felipe Cardona Zorilla, Raúl Murillo, José Jerónimo, Vivien Tsu, André Lopes Carvalho, Carlos Ferreira Gil, Cinthya Sternberg, Alfonso Dueñas‐González, Dennis C. Sgroi, Mauricio Cuello, Rodrigo Fresco, Rui Manuel Reis, Guiseppe Masera, Raúl Gabus, Raul C. Ribeiro, Renata Erthal Knust, Gustavo Ismael, Eduardo Rosenblatt, Berta Roth, Luisa L. Villa, Argelia Lara Solares, Marta León, Isabel Torres‐Vigil, Alfredo Covarrubias‐Gómez, Andrés Hernández, Mariela Bertolino, Gilberto Schwartsmann, Sergio Santillana, Francisco J. Esteva, Luis Fein, Max S. Mano, Henry Gómez, Marc Hurlbert, Alessandra Durstine, Gustavo S. Azenha - The Lancet Oncology 2013 cited by 504